본문 바로가기
KERD
논문KCI 등재

Biomarkers in Heart Failure: From Research to Clinical Practice

Berezin Alexander E.|Berezin Alexander A.
대한진단검사의학회 (Korean Society For Laboratory Medicine)|2023.05|Annals of Laboratory Medicine|제43권 제3호|pp. 225-236|DOI 10.3343/alm.2023.43.3.225

2

조회

0

다운로드

0

인용

0

참고문헌

키워드

ManagementPredictionHeart failureCardiac BiomarkersMultiple Biomarker Models
주제분류병리학

초록

The aim of this narrative review is to summarize contemporary evidence on the use of circulating cardiac biomarkers of heart failure (HF) and to identify a promising biomarker model for clinical use in personalized point-of-care HF management. We discuss the reported biomarkers of HF classified into clusters, including myocardial stretch and biomechanical stress; cardiac myocyte injury; systemic, adipocyte tissue, and microvascular inflammation; cardiac fibrosis and matrix remodeling; neurohumoral activation and oxidative stress; impaired endothelial function and integrity; and renal and skeletal muscle dysfunction. We focus on the benefits and drawbacks of biomarker-guided assistance in daily clinical management of patients with HF. In addition, we provide clear information on the role of alternative biomarkers and future directions with the aim of improving the predictive ability and reproducibility of multiple biomarker models and advancing genomic, transcriptomic, proteomic, and metabolomic evaluations.

Abstract

The aim of this narrative review is to summarize contemporary evidence on the use of circulating cardiac biomarkers of heart failure (HF) and to identify a promising biomarker model for clinical use in personalized point-of-care HF management. We discuss the reported biomarkers of HF classified into clusters, including myocardial stretch and biomechanical stress; cardiac myocyte injury; systemic, adipocyte tissue, and microvascular inflammation; cardiac fibrosis and matrix remodeling; neurohumoral activation and oxidative stress; impaired endothelial function and integrity; and renal and skeletal muscle dysfunction. We focus on the benefits and drawbacks of biomarker-guided assistance in daily clinical management of patients with HF. In addition, we provide clear information on the role of alternative biomarkers and future directions with the aim of improving the predictive ability and reproducibility of multiple biomarker models and advancing genomic, transcriptomic, proteomic, and metabolomic evaluations.

참고문헌 (96)

  1. Groenewegen A, "Epidemiology of heart failure", Eur J Heart Fail, 22, pp.1342~1356 (2020)
  2. Vasan RS, "Epidemiology of left ventricular systolic dysfunction and heart failure in the Framingham study : an echocardiographic study over 3 decades", JACC Cardiovasc Imaging, 11, pp.1~11 (2018)
  3. Roger VL, "Epidemiology of heart failure : A contemporary perspective", Circ Res, 128, pp.1421~1434 (2021)
  4. Daw P, "Barriers and facilitators to implementation of a home-based cardiac rehabilitation programme for patients with heart failure in the NHS : a mixed-methods study", BMJ Open, 12, pp.e060221~ (2022)
  5. Shah KS, "Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes", J Am Coll Cardiol, 70, pp.2476~2486 (2017)
  6. Bergamasco A, "Epidemiology of asymptomatic pre-heart failure : a systematic review", Curr Heart Fail Rep, 19, pp.146~156 (2022)
  7. Toth PP, "Heart failure with preserved ejection fraction : strategies for disease management and emerging therapeutic approaches", Postgrad Med, 133, pp.125~139 (2021)
  8. Berezin AE, "Point-of-care heart failure platform : where are we now and where are we going to?", Expert Rev Cardiovasc Ther, 20, pp.419~429 (2022)
  9. McDonagh TA, "2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC", Eur J Heart Fail, 42, pp.3599~3726 (2021)
  10. Heidenreich PA, "2022 AHA", ACC, American Heart Association joint committee on clinical practice guidelines, pp.Circulation, 2022[DOI]
  11. Savic-Radojevic A, "Novel biomarkers of heart failure", Adv Clin Chem, 79, pp.93~152 (2017)
  12. Omran F, "Cardiovascular biomarkers : lessons of the past and prospects for the future", Int J Mol Sci, 23, pp.5680~ (2022)
  13. Bozkurt B, "Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: endorsed by the Canadian Heart Failure Society, Heart Failure Association of India. Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association", Eur J Heart Fail, 23, pp.352~380 (2021)
  14. Upadhya B, "Heart failure with preserved ejection fraction : new approaches to diagnosis and management", Clin Cardiol, 43, pp.145~155 (2020)
  15. Mentz RJ, "Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction", J Am Coll Cardiol, 64, pp.2281~2293 (2014)
  16. Sartipy U, "Atrial fibrillation in heart failure with preserved, mid-range, and reduced ejection fraction", JACC Heart Fail, 5, pp.565~574 (2017)
  17. Méndez-Bailón M, "Clinical characteristics, management, and in-hospital mortality in patients with heart failure with reduced ejection fraction according to sex and the presence of type 2 diabetes mellitus", J Clin Med, 11, pp.1030~ (2022)
  18. Swaraj S, "Heart Failure with Reduced Ejection Fraction-Does Sex Matter?", Curr Heart Fail Rep, 18, pp.345~352 (2021)
  19. Wilcox JE, "Heart failure with recovered left ventricular ejection fraction : JACC scientific expert panel", J Am Coll Cardiol, 76, pp.719~734 (2020)
  20. Kapłon-Cieślicka A, "A comprehensive characterization of acute heart failure with preserved versus mildly reduced versus reduced ejection fraction-insights from the ESC-HFA EORP Heart Failure Long-Term Registry", Eur J Heart Fail, 24, pp.335~350 (2022)
  21. Burnett H, "Thirty years of evidence on the efficacy of drug treatments for chronic heart failure with reduced ejection fraction : A network meta-analysis", Circ Heart Fail, 10, pp.e003529~ (2017)
  22. Piek A, "Novel heart failure biomarkers : why do we fail to exploit their potential?", Crit Rev Clin Lab Sci, 55, pp.246~263 (2018)
  23. Nakagawa Y, "Atrial and brain natriuretic peptides : hormones secreted from the heart", Peptides, 111, pp.18~25 (2019)
  24. Volpe M, "The natriuretic peptides system in the pathophysiology of heart failure : from molecular basis to treatment", Clin Sci, 130, pp.57~77 (2016)
  25. Homar V, "Natriuretic peptides for heart failure screening in nursing homes : a systematic review", Heart Fail Rev, 26, pp.1131~1140 (2021)
  26. Gohar A, "Mid-regional pro-atrial natriuretic peptide for the early detection of non-acute heart failure", Eur J Heart Fail, 21, pp.1219~1227 (2019)
  27. Chen Y, "et al Diagnostic value of MR-proANP for heart failure in patients with acute dyspnea : a meta-analysis", Acta Cardiol, 75, pp.68~74 (2020)
  28. Mueller C, "Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations", Eur J Heart Fail, 21, pp.715~731 (2019)
  29. Gaborit FS, "Diagnostic utility of MR-proANP and NT-proBNP in elderly outpatients with a high risk of heart failure : the Copenhagen heart failure risk study", Biomarkers, 25, pp.248~259 (2020)
  30. Han ZJ, "Diagnostic accuracy of natriuretic peptides for heart failure in patients with pleural effusion : A systematic review and updated meta-analysis", PLoS One, 10, pp.e0134376~ (2015)
  31. Tanase DM, "Natriuretic peptides in heart failure with preserved left ventricular ejection fraction : from molecular evidences to clinical implications", Int J Mol Sci, 20, pp.2629~ (2019)
  32. D’Elia E, "Neprilysin inhibition in heart failure : mechanisms and substrates beyond modulating natriuretic peptides", Eur J Heart Fail, 19, pp.710~717 (2017)
  33. Dini FL, "Optimizing management of heart failure by using echo and natriuretic peptides in the outpatient unit", Adv Exp Med Biol, 1067, pp.145~159 (2018)
  34. Israr MZ, "Implications of serial measurements of natriuretic peptides in heart failure : insights from BioStat-CHF", Eur J Heart Fail, 22, pp.1486~1490 (2020)
  35. Felker GM, "Effect of natriuretic peptide-guided therapy on hospitalization or cardiovascular mortality in high-risk patients with heart failure and reduced ejection fraction : A randomized clinical trial", JAMA, 318, pp.713~720 (2017)
  36. Zhang J, "Dynamic risk stratification using serial measurements of plasma concentrations of natriuretic peptides in patients with heart failure", Int J Cardiol, 269, pp.196~200 (2018)
  37. Dini FL, "Combining echo and natriuretic peptides to guide heart failure care in the outpatient setting : A position paper", Eur J Clin Invest, 47 (2017)
  38. Werhahn SM, "NT-proBNP as a marker for atrial fibrillation and heart failure in four observational outpatient trials", ESC Heart Fail, 9, pp.100~109 (2022)
  39. Griffin EA, "Cost-effectiveness analysis of natriuretic peptide testing and specialist management in patients with suspected acute heart failure", Value Health, 20, pp.1025~1033 (2017)
  40. Mohiuddin S, "Model-based cost-effectiveness analysis of B-type natriuretic peptide-guided care in patients with heart failure", BMJ Open, 6, pp.e014010~ (2016)
  41. Jarolim P, "High sensitivity cardiac troponin assays in the clinical laboratories", Clin Chem Lab Med, 53, pp.635~652 (2015)
  42. Wang XY, "The biomarkers for acute myocardial infarction and heart failure", Biomed Res Int, 2020, pp.2018035~ (2020)
  43. Omland T, "Troponins in heart failure", Clin Chim Acta, 443, pp.78~84 (2015)
  44. Nagarajan V, "Prognostic value of cardiac troponin in chronic stable heart failure : a systematic review", Heart, 98, pp.1778~1786 (2012)
  45. Aimo A, "High-sensitivity troponin T, NT-proBNP and glomerular filtration rate: A multimarker strategy for risk stratification in chronic heart failure", Int J Cardiol, 277, pp.166~172 (2019)
  46. Packer M, "Concentration-dependent clinical and prognostic importance of high-sensitivity cardiac troponin T in heart failure and a reduced ejection fraction and the influence of empagliflozin : the EMPEROR-Reduced trial", Eur J Heart Fail, 23, pp.1529~1538 (2021)
  47. Aimo A, "Prognostic value of high-sensitivity troponin T in chronic heart failure : an individual patient data meta-analysis", Circulation, 137, pp.286~297 (2018)
  48. Wettersten N, "Role of cardiac troponin levels in acute heart failure", Card Fail Rev, 1, pp.102~106 (2015)
  49. Vergaro G, "Circulating levels and prognostic cut-offs of sST2, hs-cTnT, and NT-proBNP in women vs. men with chronic heart failure", ESC Heart Fail, 9, pp.2084~2095 (2022)
  50. Goel H, "Heart-type fatty acid-binding protein : an overlooked cardiac biomarker", Ann Med, 52, pp.444~461 (2020)
  51. Young JM, "Heart fatty acid binding protein and cardiac troponin : development of an optimal rule-out strategy for acute myocardial infarction", BMC Emerg Med, 16, pp.34~ (2016)
  52. Rezar R, "Heart-type fatty acid-binding protein(H-FABP)and its role as a biomarker in heart failure : what do we know so far?", J Clin Med, 9, pp.164~ (2020)
  53. Simeunovic D, "Glutathione transferase P1 polymorphism might be a risk determinant in heart failure", Dis Markers, 2019, pp.6984845~ (2019)
  54. Andrukhova O, "Serum glutathione S-transferase P1 1 in prediction of cardiac function", J Card Fail, 18, pp.253~261 (2012)
  55. Bošnjak I, "Prognostic value of galectin-3 in patients with heart failure", Dis Markers, 2015, pp.690205~ (2015)
  56. Henderson NC, "Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis", Am J Pathol, 172, pp.288~298 (2008)
  57. Reifenberg K, "Interferon-gamma induces chronic active myocarditis and cardiomyopathy in transgenic mice", Am J Pathol, 171, pp.463~472 (2007)
  58. McMurray JJ, "Clinical practice. Systolic heart failure", N Engl J Med, 362, pp.228~238 (2010)
  59. McCullough PA, "Galectin-3 : a novel blood test for the evaluation and management of patients with heart failure", Rev Cardiovasc Med, 12, pp.200~210 (2011)
  60. Bansal N, "Change in cardiac biomarkers and risk of incident heart failure and atrial fibrillation in CKD : the chronic renal insufficiency cohort(CRIC)study", Am J Kidney Dis, 77, pp.907~919 (2021)
  61. de Boer RA, "Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction", Ann Med, 43, pp.60~68 (2011)
  62. Motiwala SR, "Serial measurement of galectin-3 in patients with chronic heart failure : results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy(PROTECT)study", Eur J Heart Fail, 15, pp.1157~1163 (2013)
  63. Pascual-Figal DA, "Clinical relevance of sST2 in cardiac diseases", Clin Chem Lab Med, 54, pp.29~35 (2016)
  64. Lotierzo M, "sST2 as a value-added biomarker in heart failure", Clin Chim Acta, 501, pp.120~130 (2020)
  65. Vergaro G, "Cardiac biomarkers retain prognostic significance in patients with heart failure and chronic obstructive pulmonary disease", J Cardiovasc Med, 23, pp.28~36 (2022)
  66. Emdin M, "sST2 predicts outcome in chronic heart failure beyond NT-proBNP and high-sensitivity troponin T", J Am Coll Cardiol, 72, pp.2309~2320 (2018)
  67. Huang A, "Prognostic value of sST2 and NT-proBNP at admission in heart failure with preserved, mid-ranged and reduced ejection fraction", Acta Cardiol, 73, pp.41~48 (2018)
  68. Aimo A, "Clinical and prognostic significance of sST2 in heart failure : JACC review topic of the week", J Am Coll Cardiol, 74, pp.2193~2203 (2019)
  69. Nikolov A, "Extracellular matrix in heart disease : focus on circulating collagen type I and III derived peptides as biomarkers of myocardial fibrosis and their potential in the prognosis of heart failure : A concise review", Metabolites, 12, pp.297~ (2022)
  70. Flevari P, "Serum markers of deranged myocardial collagen turnover : their relation to malignant ventricular arrhythmias in cardioverter-defibrillator recipients with heart failure", Am Heart J, 164, pp.530~537 (2012)
  71. He T, "Serum and urinary biomarkers of collagen type-I turnover predict prognosis in patients with heart failure", Clin Transl Med, 11, pp.e267~ (2021)
  72. Tziakas DN, "et al Independent and additive prognostic ability of serum carboxy-terminal telopeptide of collagen type-I in heart failure patients : a multi-marker approach with high-negative predictive value to rule out long-term adverse events", Eur J Prev Cardiol, 19, pp.62~71 (2012)
  73. Chatzikyriakou SV, "Circulating levels of a biomarker of collagen metabolism are associated with health-related quality of life in patients with chronic heart failure", Qual Life Res, 21, pp.143~153 (2012)
  74. Duprez DA, "Predictive value of collagen biomarkers for heart failure with and without preserved ejection fraction : MESA(multi-ethnic study of atherosclerosis)", J Am Heart Assoc, 7, pp.e007885~ (2018)
  75. Berezin AE, "Biomarkers in disease: methods, discoveries and applications" (2015), Springer
  76. Berezin AE, "Diabetes mellitus related biomarker : the predictive role of growth-differentiation factor-15", Diabetes Metab Syndr, 10, pp.S154~7 (2016)
  77. Emmerson PJ, "The metabolic effects of GDF15 are mediated by the orphan receptor GFRAL", Nat Med, 23, pp.1215~1219 (2017)
  78. Rochette L, "GDF15 and cardiac cells : current concepts and new insights", Int J Mol Sci, 22, pp.8889~ (2021)
  79. Li N, "Plasma growth differentiation factor-15 in patients with"lone"atrial fibrillation", J Clin Lab Anal, 36, pp.e24373~ (2022)
  80. Matusik PT, "Association of NT-proBNP and GDF-15 with markers of a prothrombotic state in patients with atrial fibrillation off anticoagulation", Clin Res Cardiol, 109, pp.426~434 (2020)
  81. Wang Z, "The impact of growth differentiation factor 15 on the risk of cardiovascular diseases : two-sample Mendelian randomization study", BMC Cardiovasc Disord, 20, pp.462~ (2020)
  82. Ayoub KF, "Immunity, inflammation, and oxidative stress in heart failure: emerging molecular targets", Cardiovasc Drugs Ther, 31, pp.593~608 (2017)
  83. Sanders-van Wijk S, "Proteomic evaluation of the comorbidity-inflammation paradigm in heart failure with preserved ejection fraction : results from the PROMIS-HFpEF study", Circulation, 142, pp.2029~2044 (2020)
  84. van Veldhuisen DJ, "Biomarkers of renal injury and function: diagnostic, prognostic and therapeutic implications in heart failure", Eur Heart J, 37, pp.2577~2585 (2016)
  85. Nowak C, "Kidney disease biomarkers improve heart failure risk prediction in the general population", Circ Heart Fail, 13, pp.e006904~ (2020)
  86. Nishikimi T, "Adrenomedullin as a biomarker of heart failure", Heart Fail Clin, 14, pp.49~55 (2018)
  87. Gegenhuber A, "Comparative evaluation of B-type natriuretic peptide, mid-regional pro-A-type natriuretic peptide, mid-regional pro-adrenomedullin, and copeptin to predict 1-year mortality in patients with acute destabilized heart failure", J Card Fail, 13, pp.42~49 (2007)
  88. Lubrano V, "Role of oxidative stress-related biomarkers in heart failure: galectin 3, α1-antitrypsin and LOX-1: new therapeutic perspective?", Mol Cell Biochem, 464, pp.143~152 (2020)
  89. Berezin AE, "Myokines and heart failure: challenging role in adverse cardiac remodeling, myopathy, and clinical outcomes", Dis Markers, 2021, pp.6644631~ (2021)
  90. Berezin AA, "The effect of SGLT2 inhibitor dapagliflozin on serum levels of apelin in T2DM patients with heart failure", Biomedicines, 10, pp.1751~ (2022)
  91. Berezin AA, "Serum levels of irisin predict cumulative clinical outcomes in heart failure patients with type 2 diabetes mellitus", Front Physiol, 13, pp.922775~ (2022)
  92. Chirinos JA, "Multiple plasma biomarkers for risk stratification in patients with heart failure and preserved ejection fraction", J Am Coll Cardiol, 75, pp.1281~1295 (2020)
  93. Bayes-Genis A, "Multimarker testing with ST2 in chronic heart failure", Am J Cardiol, 115(S7), pp.76B~80B (2015)
  94. Topf A, "The diagnostic and therapeutic value of multimarker analysis in heart failure. An approach to biomarker-targeted therapy", Front Cardiovasc Med, 7, pp.579567~ (2020)
  95. Aldweib N, "Serial cardiac biomarker assessment in adults with congenital heart disease hospitalized for decompensated heart failure☆", Int J Cardiol Congenit Heart Dis, 7, pp.100336~ (2022)
  96. Berezin AE, "Cell-free long noncoding RNAs as predictive biomarkers for cardiovascular diseases", Int J Cardiol, 359, pp.115~117 (2022)

관련 논문AI추천

Breakthrough in heart failure with preserved ejection fraction: are we there yet?Carolyn Su Ping Lam, Shir Lynn Lim대한내과학회 · The Korean Journal of Internal Medicine2016 · 제31권 제1호Prognostic Value of Combined Biomarkers in Patients With Heart Failure: The Heartmarker ScoreBoer Arjen-Kars, Bouwmeester Sjoerd, Dekker Lukas R., Houthuizen Patrick, Scharnhorst Volkher, van der Stam Jonna A., van Loon Saskia L. M., van Riel Natal A. W.대한진단검사의학회 · Annals of Laboratory Medicine2023 · 제43권 제3호Update on heart failure management and future directions박명수, 윤종찬, 최홍미대한내과학회 · The Korean Journal of Internal Medicine2019 · 제34권 제1호Heart failure with preserved ejection fraction: insights from recent clinical researchesMi-Na Kim, Seong-Mi Park대한내과학회 · The Korean Journal of Internal Medicine2020 · 제35권 제3호Role of cardiac imaging in management of heart failureSeong-Mi Park, So Ree Kim대한내과학회 · The Korean Journal of Internal Medicine2023 · 제38권 제5호The Role of Cardiac Biomarkers in the Diagnosis and Management of Patients Presenting with Suspected Acute Coronary SyndromeEric Christenson, Robert H. Christenson대한진단검사의학회 · Annals of Laboratory Medicine2013 · 제33권 제5호

이 간행물의 다른 논문 (16건)

Apolipoprotein B, Non-HDL Cholesterol, and LDL Cholesterol as Markers for Atherosclerotic Cardiovascular Disease Risk Assessment윤여민pp. 221-222Rapid Targeted Genomic Testing: A Powerful Tool for Diagnostic Evaluation of Critically Ill Neonates and Infants With Suspected Genetic Diseases장미애pp. 223-224Associations of LDL Cholesterol, Non-HDL Cholesterol, and Apolipoprotein B With Cardiovascular Disease Occurrence in Adults: Korean Genome and Epidemiology StudyYun Shin Young, Lim Jong-Baeck, 이상국, Rim John Hoon, Kang Hyeinpp. 237-243Accuracy of the New Creatinine-based Equations for Estimating Glomerular Filtration Rate in Koreans전사일, 민원기, Lee Woochang, Jeong Tae-Dong, Hong Jinyoungpp. 244-252Prognostic Value of Combined Biomarkers in Patients With Heart Failure: The Heartmarker Scorevan der Stam Jonna A., Bouwmeester Sjoerd, van Loon Saskia L. M., van Riel Natal A. W., Dekker Lukas R., Boer Arjen-Kars, Houthuizen Patrick, Scharnhorst Volkherpp. 253-262
원문 보기